Terms: = Breast cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
1862 results:
1. Improving quality of life after breast cancer: a comparison of two microsurgical treatment options for breast cancer-related lymphedema (BCRL).
Seidenstuecker K; Fertsch S; Ghazaleh AA; Fabi A; Stoffel J; Bukowiecki J; Wolter A; Aghlmandi S; Nadella A; Halbeisen FS; Andree C; Haug MD; Schaefer DJ; Handschin TM; Kappos EA
Clin Exp Med; 2024 Apr; 24(1):82. PubMed ID: 38653874
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer.
Bagheri M; Mohamed GA; Mohamed Saleem MA; Ognjenovic NB; Lu H; Kolling FW; Wilkins OM; Das S; LaCroix IS; Nagaraj SH; Muller KE; Gerber SA; Miller TW; Pattabiraman DR
Cell Rep Med; 2024 Apr; 5(4):101504. PubMed ID: 38593809
[TBL] [Abstract] [Full Text] [Related]
3. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
Lin D; Sturgeon KM; Muscat JE; Zhou S; Hobkirk AL; O'Brien KM; Sandler DP; Thompson CL
Breast Cancer; 2024 May; 31(3):519-528. PubMed ID: 38564089
[TBL] [Abstract] [Full Text] [Related]
4. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
5. Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
Vo K; Ladbury C; Yoon S; Bazan J; Glaser S; Amini A
Breast Cancer; 2024 May; 31(3):485-495. PubMed ID: 38507145
[TBL] [Abstract] [Full Text] [Related]
6. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
7. [Research Status and Trend of Screening for Women's Common Diseases in China].
Fan ZX; Yan MY; Pei CY; Lei QR; Ma J; Liu YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Feb; 46(1):33-38. PubMed ID: 38433628
[TBL] [Abstract] [Full Text] [Related]
8. The Association Between Mammography Screening Frequency and breast cancer treatment and Outcomes: A Retrospective Cohort Study.
Liu Y; Gordon AS; Eleff M; Barron JJ; Chi WC
J Breast Imaging; 2023 Feb; 5(1):21-29. PubMed ID: 38416960
[TBL] [Abstract] [Full Text] [Related]
9. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the treatment of Triple-Negative breast cancer.
Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
[TBL] [Abstract] [Full Text] [Related]
10. Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor
Kaneko K; Nagao M; Ueda K; Yamamoto A; Sakai S
Ann Nucl Med; 2024 Apr; 38(4):278-287. PubMed ID: 38386272
[TBL] [Abstract] [Full Text] [Related]
11. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis.
Coronado PJ; Gómez A; Iglesias E; Fasero M; Baquedano L; Sánchez S; Ramírez-Polo I; de la Viuda E; Otero B; Llaneza P; Mendoza N; Lubián DM;
Menopause; 2024 Mar; 31(3):234-242. PubMed ID: 38385734
[TBL] [Abstract] [Full Text] [Related]
12. The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
[TBL] [Abstract] [Full Text] [Related]
13. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,
Shah M; Lingam H; Gao X; Gittleman H; Fiero MH; Krol D; Biel N; Ricks TK; Fu W; Hamed S; Li F; Sun JJ; Fan J; Schuck R; Grimstein M; Tang L; Kalavar S; Abukhdeir A; Pathak A; Ghosh S; Bulatao I; Tilley A; Pierce WF; Mixter BD; Tang S; Pazdur R; Kluetz P; Amiri-Kordestani L
J Clin Oncol; 2024 Apr; 42(10):1193-1201. PubMed ID: 38381994
[TBL] [Abstract] [Full Text] [Related]
14. Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.
Zhang M; Zhang G; Niu Y; Zhang G; Ji Y; Yan X; Zhang X; Wang Q; Jing X; Wang J; Ma Z; Wang H
Nat Commun; 2024 Feb; 15(1):1512. PubMed ID: 38374204
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of Moxibustion for cancer-Related Fatigue in Patients with breast cancer: A Systematic Review and meta-Analysis.
Bae HR; Kim EJ; Ahn YC; Cho JH; Son CG; Lee NH
Integr Cancer Ther; 2024; 23():15347354241233226. PubMed ID: 38372234
[TBL] [Abstract] [Full Text] [Related]
16. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
17. Availability and Geographic Access to Hospital-Based breast cancer Diagnostic Services in Ghana.
Price MD; Rositch AF; Dedey F; Mali ME; Brownson KE; Nsaful J; Tounkara M; Price RR; Sutherland EK
JCO Glob Oncol; 2024 Feb; 10():e2300231. PubMed ID: 38330275
[TBL] [Abstract] [Full Text] [Related]
18. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
[TBL] [Abstract] [Full Text] [Related]
19. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
20. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Li Q; Liu J; Zhang Q; Ouyang Q; Zhang Y; Liu Q; Sun T; Ye F; Zhang B; Xia S; Zhang B; Xu B
Nat Commun; 2024 Feb; 15(1):1015. PubMed ID: 38310192
[TBL] [Abstract] [Full Text] [Related]
[Next]
